The pathophysiology of major depressive disorder (MDD) is thought to result from impaired
connectivity between key brain networks. Gamma-aminobutyric acid (GABA) is the key …

Gamma-aminobutyric acid (GABA) is a non-protein amino acid widely distributed in nature
and extensively explored for its numerous physiological functions and effects on metabolic …

Objective: To evaluate the efficacy and safety of zuranolone, an investigational neuroactive
steroid and GABA A receptor positive allosteric modulator, in major depressive disorder …

Over the last few years, the microbiome has emerged as a high-priority research area to
discover missing links between brain health and gut dysbiosis. Emerging evidence suggests …

A functional interplay of bottom‐up and top‐down processing allows an individual to
appropriately respond to the dynamic environment around them. These processing …

Background A significant proportion of adults with major depressive disorder (MDD) do not
respond to treatments which are currently used in clinical practice such as first-generation …

The focus on managing Alzheimer's disease (AD) is shifting towards prevention through
lifestyle modification instead of treatments since the currently available treatment options are …

Ketamine, functioning as a channel blocker of the excitatory glutamate-gated N-methyl-d-
aspartate (NMDA) receptors, displays compelling fast-acting and sustained antidepressant …

Patients with cancer are at greater risk of developing depression in comparison to the
general population and this is associated with serious adverse effects, such as poorer …

Major depressive disorder (MDD) is a mental health disorder that can cause disability and
functional impairment that standard-of-care (SOC) antidepressant therapies (ADTs) can take …